This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Anisodamine
Accession Number
DB11785
Type
Small Molecule
Groups
Investigational
Description

Anisodamine has been investigated for the treatment of Intestinal Diseases.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Anisodamine Hydrochloride13NCM8S773131674-05-0TXJYFXBXRUTHSF-YXGOVGSCSA-N
Categories
UNII
01343Q8EL8
CAS number
55869-99-3
Weight
Average: 305.374
Monoisotopic: 305.162708225
Chemical Formula
C17H23NO4
InChI Key
WTQYWNWRJNXDEG-RBZJEDDUSA-N
InChI
InChI=1S/C17H23NO4/c1-18-12-7-13(9-15(18)16(20)8-12)22-17(21)14(10-19)11-5-3-2-4-6-11/h2-6,12-16,19-20H,7-10H2,1H3/t12-,13-,14+,15+,16-/m0/s1
IUPAC Name
(1R,3S,5R,6S)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl (2S)-3-hydroxy-2-phenylpropanoate
SMILES
CN1[C@@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Anisodamine.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Anisodamine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Anisodamine is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Anisodamine is combined with 5-androstenedione.Experimental, Illicit
AbciximabAnisodamine may increase the anticoagulant activities of Abciximab.Approved
AcebutololAnisodamine may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Anisodamine is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Anisodamine is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolAnisodamine may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcepromazineAcepromazine may decrease the vasoconstricting activities of Anisodamine.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Anisodamine is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Anisodamine.Approved
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Anisodamine.Experimental, Investigational
AlclofenacThe risk or severity of adverse effects can be increased when Anisodamine is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Anisodamine is combined with Alendronic acid.Approved
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Anisodamine.Approved, Investigational
AliskirenAnisodamine may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Anisodamine is combined with Alminoprofen.Experimental
AlprenololAnisodamine may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Anisodamine.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Anisodamine is combined with Amcinonide.Approved
AmilorideAnisodamine may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Anisodamine is combined with Aminosalicylic Acid.Approved
AmiodaroneThe therapeutic efficacy of Anisodamine can be increased when used in combination with Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may decrease the vasoconstricting activities of Anisodamine.Approved
AmoxapineAmoxapine may decrease the vasoconstricting activities of Anisodamine.Approved
AncrodAnisodamine may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Anisodamine.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anisodamine is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Anisodamine is combined with anecortave acetate.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Antipyrine.Approved, Investigational
Antithrombin III humanAnisodamine may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Antrafenine.Approved
ApixabanAnisodamine may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Anisodamine is combined with Apocynin.Investigational
ApramycinAnisodamine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Anisodamine.Approved, Investigational
ArbekacinAnisodamine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinAnisodamine may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanAnisodamine may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleAripiprazole may decrease the vasoconstricting activities of Anisodamine.Approved, Investigational
ArotinololAnisodamine may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineAsenapine may decrease the vasoconstricting activities of Anisodamine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Atamestane.Investigational
AtenololAnisodamine may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Anisodamine.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Anisodamine.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Anisodamine is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Anisodamine.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Anisodamine.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Anisodamine is combined with Balsalazide.Approved, Investigational
BecaplerminAnisodamine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BefunololAnisodamine may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinAnisodamine may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Anisodamine is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Anisodamine is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Anisodamine.Approved
BenorilateThe risk or severity of adverse effects can be increased when Anisodamine is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Anisodamine.Withdrawn
BenzphetamineThe therapeutic efficacy of Benzphetamine can be decreased when used in combination with Anisodamine.Approved, Illicit
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Anisodamine.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Benzydamine.Approved
Benzylpenicilloyl PolylysineAnisodamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Anisodamine.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Betamethasone.Approved, Vet Approved
BetaxololAnisodamine may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Anisodamine.Approved, Investigational
BevantololAnisodamine may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Anisodamine is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Anisodamine.Approved, Investigational
BisoprololAnisodamine may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinAnisodamine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololAnisodamine may decrease the antihypertensive activities of Bopindolol.Approved
BrexpiprazoleBrexpiprazole may decrease the vasoconstricting activities of Anisodamine.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Anisodamine is combined with Bromfenac.Approved
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Anisodamine.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Bucillamine.Investigational
BucindololBucindolol may decrease the vasoconstricting activities of Anisodamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Anisodamine is combined with Bufexamac.Approved, Experimental
BufuralolAnisodamine may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Anisodamine.Approved
BunazosinBunazosin may decrease the vasoconstricting activities of Anisodamine.Investigational
BupranololAnisodamine may decrease the antihypertensive activities of Bupranolol.Approved
BupropionThe metabolism of Anisodamine can be decreased when combined with Bupropion.Approved
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Anisodamine.Approved
CaffeineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Caffeine.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Anisodamine.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Anisodamine.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Anisodamine is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Anisodamine is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Anisodamine is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Anisodamine is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Anisodamine.Approved
CarprofenThe risk or severity of adverse effects can be increased when Anisodamine is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololAnisodamine may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolThe therapeutic efficacy of Anisodamine can be decreased when used in combination with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Anisodamine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Anisodamine is combined with Celecoxib.Approved, Investigational
CeliprololAnisodamine may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinAnisodamine may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Anisodamine.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Anisodamine.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Anisodamine is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorpromazineChlorpromazine may decrease the vasoconstricting activities of Anisodamine.Approved, Investigational, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Anisodamine.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Anisodamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Anisodamine is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Anisodamine is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Anisodamine is combined with Cilazapril.Approved
CimetidineThe metabolism of Anisodamine can be decreased when combined with Cimetidine.Approved, Investigational
CimicoxibThe risk or severity of adverse effects can be increased when Anisodamine is combined with Cimicoxib.Investigational
CinoxacinAnisodamine may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CisplatinThe risk or severity of adverse effects can be increased when Anisodamine is combined with Cisplatin.Approved
ClemastineThe metabolism of Anisodamine can be decreased when combined with Clemastine.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Anisodamine is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Anisodamine is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Anisodamine is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Anisodamine.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Anisodamine.Vet Approved
CloranololAnisodamine may decrease the antihypertensive activities of Cloranolol.Experimental
ClozapineClozapine may decrease the vasoconstricting activities of Anisodamine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Anisodamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Anisodamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Anisodamine is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Anisodamine is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Anisodamine.Approved, Investigational
CyclobenzaprineThe risk or severity of hypertension can be increased when Cyclobenzaprine is combined with Anisodamine.Approved
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Anisodamine.Experimental
CyclosporineThe risk or severity of hyperkalemia can be increased when Anisodamine is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateAnisodamine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinAnisodamine may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidAnisodamine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapiprazoleDapiprazole may decrease the vasoconstricting activities of Anisodamine.Approved
DarexabanAnisodamine may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Anisodamine is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Anisodamine is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Anisodamine is combined with Delapril.Investigational
DesipramineAnisodamine may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinAnisodamine may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Anisodamine is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Anisodamine is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Anisodamine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Anisodamine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineThe serum concentration of Anisodamine can be increased when it is combined with Desvenlafaxine.Approved, Investigational
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Anisodamine is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Anisodamine is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Anisodamine.Approved, Investigational
DextranAnisodamine may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DextroamphetamineDextroamphetamine may decrease the vasoconstricting activities of Anisodamine.Approved, Illicit
DibekacinAnisodamine may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Anisodamine is combined with Dibotermin alfa.Approved, Investigational
DiclofenacDiclofenac may decrease the antihypertensive activities of Anisodamine.Approved, Vet Approved
DicoumarolAnisodamine may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Anisodamine is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Anisodamine is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Anisodamine is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Anisodamine.Approved
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Anisodamine.Approved, Investigational
DihydrostreptomycinAnisodamine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemDiltiazem may increase the hypotensive activities of Anisodamine.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Anisodamine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Anisodamine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Anisodamine.Approved
DiphenhydramineThe metabolism of Anisodamine can be decreased when combined with Diphenhydramine.Approved, Investigational
DoxazosinThe therapeutic efficacy of Anisodamine can be decreased when used in combination with Doxazosin.Approved
DoxepinDoxepin may decrease the vasoconstricting activities of Anisodamine.Approved, Investigational
DronedaroneDronedarone may decrease the vasoconstricting activities of Anisodamine.Approved
DroperidolDroperidol may decrease the vasoconstricting activities of Anisodamine.Approved, Vet Approved
DrospirenoneAnisodamine may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Anisodamine is combined with Droxicam.Withdrawn
DuloxetineDuloxetine may increase the tachycardic activities of Anisodamine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Anisodamine is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Anisodamine.Investigational
Edetic AcidAnisodamine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanAnisodamine may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Anisodamine is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Anisodamine is combined with Enalaprilat.Approved
EnoxacinAnisodamine may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinAnisodamine may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Anisodamine.Experimental
EpanololAnisodamine may decrease the antihypertensive activities of Epanolol.Experimental
EpinephrineEpinephrine may decrease the vasoconstricting activities of Anisodamine.Approved, Vet Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Anisodamine.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Anisodamine.Experimental
EplerenoneAnisodamine may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Anisodamine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Anisodamine.Approved
EquileninThe risk or severity of adverse effects can be increased when Anisodamine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Anisodamine is combined with Equilin.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Anisodamine.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Anisodamine.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Anisodamine.Approved
EsatenololAnisodamine may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may decrease the vasoconstricting activities of Anisodamine.Approved, Investigational
EsmololAnisodamine may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Anisodamine is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Anisodamine.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Anisodamine is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Anisodamine is combined with Ethenzamide.Experimental
Ethyl biscoumacetateAnisodamine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Anisodamine is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Anisodamine is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Anisodamine.Approved, Investigational
EtomidateThe therapeutic efficacy of Etomidate can be decreased when used in combination with Anisodamine.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Anisodamine is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Anisodamine.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Anisodamine.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Anisodamine.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Anisodamine.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Anisodamine.Vet Approved
FentanylFentanyl may increase the bradycardic activities of Anisodamine.Approved, Illicit, Investigational, Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Feprazone.Experimental
Ferulic acidAnisodamine may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Anisodamine.Approved, Investigational
FleroxacinAnisodamine may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Anisodamine.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fludrocortisone.Approved, Investigational
FluindioneAnisodamine may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineAnisodamine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Anisodamine is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Anisodamine.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Anisodamine is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fluorometholone.Approved, Investigational
FluoxetineThe serum concentration of Anisodamine can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may decrease the vasoconstricting activities of Anisodamine.Approved, Investigational, Withdrawn
FluprednideneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Anisodamine.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Anisodamine is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Anisodamine is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fluticasone furoate.Approved
FluvoxamineThe metabolism of Anisodamine can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Anisodamine.Approved, Nutraceutical, Vet Approved
FondaparinuxAnisodamine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Anisodamine.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Anisodamine.Approved
FramycetinAnisodamine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
GabexateAnisodamine may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinAnisodamine may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinAnisodamine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Anisodamine.Approved, Withdrawn
GemifloxacinAnisodamine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinAnisodamine may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinAnisodamine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AAnisodamine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Anisodamine is combined with Ginseng.Approved, Investigational, Nutraceutical
GlimepirideAnisodamine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideAnisodamine may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideAnisodamine may increase the hypoglycemic activities of Glyburide.Approved
GrepafloxacinAnisodamine may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Anisodamine is combined with Guacetisal.Experimental
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Anisodamine.Approved, Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Anisodamine is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Anisodamine is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Anisodamine is combined with HE3286.Investigational
HeparinAnisodamine may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Higenamine.Investigational
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Anisodamine.Approved, Investigational
HydralazineAnisodamine may decrease the antihypertensive activities of Hydralazine.Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Anisodamine.Approved, Investigational
Hygromycin BAnisodamine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Anisodamine.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Anisodamine.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Anisodamine.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Anisodamine is combined with Icosapent.Approved, Nutraceutical
IdraparinuxAnisodamine may increase the anticoagulant activities of Idraparinux.Investigational
IloperidoneIloperidone may decrease the vasoconstricting activities of Anisodamine.Approved
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Anisodamine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Anisodamine is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Anisodamine is combined with Imidazole salicylate.Experimental
ImipramineImipramine may decrease the vasoconstricting activities of Anisodamine.Approved
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Anisodamine.Approved
IndenololAnisodamine may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Anisodamine is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Anisodamine is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Anisodamine.Withdrawn
IndoraminIndoramin may decrease the vasoconstricting activities of Anisodamine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Anisodamine.Approved, Investigational
IsepamicinAnisodamine may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Anisodamine.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Anisodamine is combined with Istaroxime.Investigational
KanamycinAnisodamine may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Anisodamine.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Anisodamine is combined with Ketoprofen.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Anisodamine.Approved
LabetalolThe therapeutic efficacy of Anisodamine can be decreased when used in combination with Labetalol.Approved
LandiololAnisodamine may decrease the antihypertensive activities of Landiolol.Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Anisodamine.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Anisodamine.Approved, Investigational
LepirudinAnisodamine may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanAnisodamine may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololAnisodamine may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololAnisodamine may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinAnisodamine may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Anisodamine.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Anisodamine.Approved, Vet Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Anisodamine.Approved, Investigational
LisdexamfetamineLisdexamfetamine may decrease the vasoconstricting activities of Anisodamine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Anisodamine is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Lisofylline.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Anisodamine.Experimental
LomefloxacinAnisodamine may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Anisodamine is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Anisodamine is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of hyperkalemia can be increased when Losartan is combined with Anisodamine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Anisodamine.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Anisodamine.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Anisodamine is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Anisodamine.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Anisodamine is combined with Magnesium salicylate.Approved
ManidipineThe metabolism of Anisodamine can be decreased when combined with Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Anisodamine.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Anisodamine is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Anisodamine is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Anisodamine is combined with Mefenamic acid.Approved
MelagatranAnisodamine may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Anisodamine is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Anisodamine is combined with Meloxicam.Approved, Vet Approved
MepindololAnisodamine may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Anisodamine.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Anisodamine.Approved
MethotrimeprazineMethotrimeprazine may decrease the vasoconstricting activities of Anisodamine.Approved, Investigational
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Anisodamine.Approved
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Anisodamine.Approved
MetipranololAnisodamine may decrease the antihypertensive activities of Metipranolol.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Anisodamine.Approved, Investigational
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Anisodamine.Approved
MetoprololThe therapeutic efficacy of Anisodamine can be decreased when used in combination with Metoprolol.Approved, Investigational
MicronomicinAnisodamine may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Anisodamine.Approved, Experimental
MilnacipranMilnacipran may increase the tachycardic activities of Anisodamine.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Anisodamine.Approved
MizoribineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Anisodamine is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Anisodamine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Anisodamine.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Anisodamine.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Nabumetone.Approved
NadololAnisodamine may decrease the antihypertensive activities of Nadolol.Approved
NadroparinAnisodamine may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatAnisodamine may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Anisodamine.Approved
Nalidixic AcidAnisodamine may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Anisodamine.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Anisodamine.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Anisodamine is combined with NCX 1022.Investigational
NeamineAnisodamine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololAnisodamine may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may decrease the vasoconstricting activities of Anisodamine.Approved, Withdrawn
NemonoxacinAnisodamine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NepafenacThe risk or severity of adverse effects can be increased when Anisodamine is combined with Nepafenac.Approved, Investigational
NetilmicinAnisodamine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe therapeutic efficacy of Anisodamine can be decreased when used in combination with Nicardipine.Approved, Investigational
NicergolineNicergoline may decrease the vasoconstricting activities of Anisodamine.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Nicotine.Approved
NifedipineThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Anisodamine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Anisodamine is combined with Niflumic Acid.Approved
NiguldipineThe therapeutic efficacy of Anisodamine can be decreased when used in combination with Niguldipine.Experimental
NimesulideNimesulide may decrease the antihypertensive activities of Anisodamine.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Anisodamine is combined with Nitroaspirin.Investigational
NorfloxacinAnisodamine may increase the neuroexcitatory activities of Norfloxacin.Approved
NortriptylineNortriptyline may decrease the vasoconstricting activities of Anisodamine.Approved
NylidrinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Anisodamine.Approved
OfloxacinAnisodamine may increase the neuroexcitatory activities of Ofloxacin.Approved
OlanzapineOlanzapine may decrease the vasoconstricting activities of Anisodamine.Approved, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Anisodamine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Anisodamine.Approved
OlsalazineAnisodamine may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Anisodamine is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Anisodamine is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Anisodamine.Vet Approved
OtamixabanAnisodamine may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Anisodamine is combined with Oxaprozin.Approved
Oxolinic acidAnisodamine may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololAnisodamine may decrease the antihypertensive activities of Oxprenolol.Approved
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Anisodamine.Approved, Investigational
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Anisodamine.Approved, Withdrawn
PaliperidonePaliperidone may decrease the vasoconstricting activities of Anisodamine.Approved
PalmidrolThe risk or severity of adverse effects can be increased when Anisodamine is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Anisodamine is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Anisodamine is combined with Parecoxib.Approved
ParoxetineThe serum concentration of Anisodamine can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Anisodamine is combined with Parthenolide.Approved, Investigational
PazufloxacinAnisodamine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinAnisodamine may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololAnisodamine may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateAnisodamine may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateAnisodamine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Anisodamine is combined with Perindopril.Approved
PhenindioneAnisodamine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe serum concentration of Anisodamine can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzaminePhenoxybenzamine may decrease the vasoconstricting activities of Anisodamine.Approved
PhenprocoumonAnisodamine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentolaminePhentolamine may decrease the vasoconstricting activities of Anisodamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Phenylbutazone.Approved, Vet Approved
PhenylephrineThe therapeutic efficacy of Phenylephrine can be decreased when used in combination with Anisodamine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Anisodamine.Approved, Investigational
PindololAnisodamine may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidAnisodamine may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Anisodamine.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Anisodamine.Approved, Investigational
Piromidic acidAnisodamine may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Anisodamine is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Anisodamine is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Anisodamine is combined with Pitolisant.Approved, Investigational
PizotifenPizotifen may decrease the vasoconstricting activities of Anisodamine.Approved
Platelet Activating FactorAnisodamine may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinAnisodamine may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Anisodamine.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Anisodamine is combined with Pomalidomide.Approved
Potassium ChlorideThe risk or severity of hyperkalemia can be increased when Potassium Chloride is combined with Anisodamine.Approved, Withdrawn
Potassium CitrateAnisodamine may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololAnisodamine may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Anisodamine.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Anisodamine is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Anisodamine is combined with Prasterone sulfate.Investigational
PrazosinPrazosin may decrease the vasoconstricting activities of Anisodamine.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Anisodamine is combined with Prednicarbate.Approved, Investigational
PrednisoneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Anisodamine can be increased when it is combined with Probenecid.Approved, Investigational
ProchlorperazineThe serum concentration of Anisodamine can be increased when it is combined with Prochlorperazine.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Anisodamine is combined with Proglumetacin.Experimental
PromazinePromazine may decrease the vasoconstricting activities of Anisodamine.Approved, Vet Approved
PromethazineThe serum concentration of Anisodamine can be increased when it is combined with Promethazine.Approved, Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Anisodamine.Approved, Investigational
PropafenoneThe risk or severity of adverse effects can be increased when Propafenone is combined with Anisodamine.Approved
PropericiazinePropericiazine may decrease the vasoconstricting activities of Anisodamine.Approved, Investigational
PropiomazinePropiomazine may decrease the vasoconstricting activities of Anisodamine.Approved
PropiverinePropiverine may decrease the vasoconstricting activities of Anisodamine.Approved, Investigational
PropranololThe therapeutic efficacy of Anisodamine can be decreased when used in combination with Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Anisodamine.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Anisodamine.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Anisodamine.Vet Approved
Protein CAnisodamine may increase the anticoagulant activities of Protein C.Approved
Protein S humanAnisodamine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeAnisodamine may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinAnisodamine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PseudoephedrineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Anisodamine.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Anisodamine.Investigational
PuromycinAnisodamine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuetiapineThe therapeutic efficacy of Anisodamine can be decreased when used in combination with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Anisodamine is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Anisodamine.Approved
QuinidineQuinidine may decrease the vasoconstricting activities of Anisodamine.Approved, Investigational
RacepinephrineRacepinephrine may decrease the vasoconstricting activities of Anisodamine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Anisodamine is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Anisodamine is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinAnisodamine may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinAnisodamine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Anisodamine is combined with Risedronate.Approved, Investigational
RisperidoneRisperidone may decrease the vasoconstricting activities of Anisodamine.Approved, Investigational
RivaroxabanAnisodamine may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Anisodamine is combined with Rofecoxib.Approved, Investigational, Withdrawn
RopiniroleThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Anisodamine.Approved, Investigational
RosoxacinAnisodamine may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinAnisodamine may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Anisodamine.Approved
SalbutamolThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Anisodamine.Approved, Vet Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Anisodamine.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Anisodamine.Approved, Investigational, Vet Approved
SalmeterolThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Anisodamine.Approved
SalsalateThe risk or severity of adverse effects can be increased when Anisodamine is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Anisodamine.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Anisodamine.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Anisodamine.Approved, Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Anisodamine is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Anisodamine is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Anisodamine.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Anisodamine is combined with Serrapeptase.Investigational
SilodosinSilodosin may decrease the vasoconstricting activities of Anisodamine.Approved
SisomicinAnisodamine may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinAnisodamine may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SotalolAnisodamine may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinAnisodamine may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Anisodamine is combined with Spirapril.Approved
SpironolactoneThe therapeutic efficacy of Anisodamine can be decreased when used in combination with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Anisodamine.Investigational
StreptomycinAnisodamine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Anisodamine.Approved
SulindacSulindac may decrease the antihypertensive activities of Anisodamine.Approved, Investigational
SulodexideAnisodamine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Anisodamine.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Anisodamine is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Suxibuzone.Experimental
TacrolimusAnisodamine may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Anisodamine.Approved
TalinololAnisodamine may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Anisodamine.Approved
TamsulosinTamsulosin may decrease the vasoconstricting activities of Anisodamine.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Anisodamine.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Anisodamine.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Anisodamine is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Anisodamine is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Anisodamine.Approved, Investigational
TemafloxacinAnisodamine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Anisodamine is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Anisodamine is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Anisodamine is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Anisodamine is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Anisodamine.Vet Approved
TerazosinTerazosin may decrease the vasoconstricting activities of Anisodamine.Approved
TerbinafineThe metabolism of Anisodamine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineAnisodamine may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Anisodamine.Approved
TertatololAnisodamine may decrease the antihypertensive activities of Tertatolol.Experimental
ThioproperazineThioproperazine may decrease the vasoconstricting activities of Anisodamine.Approved
ThioridazineThioridazine may decrease the vasoconstricting activities of Anisodamine.Approved, Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Anisodamine is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Anisodamine is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololAnisodamine may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Anisodamine is combined with Tixocortol.Approved, Withdrawn
TobramycinAnisodamine may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolazolineTolazoline may decrease the vasoconstricting activities of Anisodamine.Approved, Vet Approved
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Anisodamine.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Anisodamine is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Anisodamine.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Anisodamine is combined with Trandolapril.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Anisodamine.Approved
TrazodoneTrazodone may decrease the vasoconstricting activities of Anisodamine.Approved, Investigational
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Anisodamine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Anisodamine is combined with Triamcinolone.Approved, Vet Approved
TriamtereneAnisodamine may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Anisodamine is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Anisodamine.Approved, Vet Approved
TrifluoperazineTrifluoperazine may decrease the vasoconstricting activities of Anisodamine.Approved, Investigational
TrimazosinTrimazosin may decrease the vasoconstricting activities of Anisodamine.Experimental
TrimipramineTrimipramine may decrease the vasoconstricting activities of Anisodamine.Approved
TriptolideThe risk or severity of adverse effects can be increased when Anisodamine is combined with Triptolide.Investigational
Trolamine salicylateTrolamine salicylate may decrease the antihypertensive activities of Anisodamine.Approved
TrovafloxacinAnisodamine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinAnisodamine may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Anisodamine is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Anisodamine.Approved, Investigational
UrapidilUrapidil may decrease the vasoconstricting activities of Anisodamine.Investigational
ValaciclovirThe risk or severity of adverse effects can be increased when Anisodamine is combined with Valaciclovir.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Anisodamine is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Anisodamine.Approved, Investigational
VenlafaxineThe serum concentration of Anisodamine can be increased when it is combined with Venlafaxine.Approved
VerapamilVerapamil may increase the hypotensive activities of Anisodamine.Approved
WarfarinAnisodamine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranAnisodamine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Anisodamine.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Anisodamine.Approved, Investigational, Withdrawn
ZiprasidoneZiprasidone may decrease the vasoconstricting activities of Anisodamine.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Anisodamine is combined with Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Anisodamine.Withdrawn
ZuclopenthixolZuclopenthixol may decrease the vasoconstricting activities of Anisodamine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
6918612
PubChem Substance
347828135
ChemSpider
19969304
ChEMBL
CHEMBL2165224
Wikipedia
Anisodamine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2RecruitingTreatmentShock, Septic1
3CompletedTreatmentIntestinal Diseases1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility17.4 mg/mLALOGPS
logP0.82ALOGPS
logP0.42ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)14.44ChemAxon
pKa (Strongest Basic)8.84ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area70 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity82.13 m3·mol-1ChemAxon
Polarizability32.22 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as tropane alkaloids. These are organic compounds containing the nitrogenous bicyclic alkaloid parent N-Methyl-8-azabicyclo[3.2.1]octane.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Tropane alkaloids
Sub Class
Not Available
Direct Parent
Tropane alkaloids
Alternative Parents
Beta hydroxy acids and derivatives / Piperidines / N-alkylpyrrolidines / Benzene and substituted derivatives / Trialkylamines / Secondary alcohols / 1,2-aminoalcohols / Amino acids and derivatives / Cyclic alcohols and derivatives / Carboxylic acid esters
show 7 more
Substituents
Tropane alkaloid / Beta-hydroxy acid / Monocyclic benzene moiety / Hydroxy acid / Piperidine / N-alkylpyrrolidine / Benzenoid / Pyrrolidine / Cyclic alcohol / 1,2-aminoalcohol
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Sternieri E, Coccia CP, Pinetti D, Guerzoni S, Ferrari A: Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments. Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):981-1007. doi: 10.1517/17425255.2.6.981 . [PubMed:17125412]
  2. Brodde OE, Kroemer HK: Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53(12):814-22. [PubMed:14732961]
  3. Iwaki M, Niwa T, Bandoh S, Itoh M, Hirose H, Kawase A, Komura H: Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432. doi: 10.1016/j.dmpk.2016.08.007. Epub 2016 Sep 2. [PubMed:27836712]

Drug created on October 20, 2016 14:48 / Updated on August 02, 2018 06:29